Aspect Biosystems Ltd. news
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s protocols for differentiating stem cells into hepatocytes with the goal of developing biop
Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic
Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted liver tissues at the The Liver Meeting 2021, hosted b
Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes
Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and Islet Transplant Association Congress 202
Vancouver, BC, Canada, October 4, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mesa to be held October 12-14, 2021 in Carlsbad, CA. This is the third time that the company will be presenting at this conference.
Organized by the Alliance for Reg
Jack Harvey joins the company as Senior Vice President of Process Development & Manufacturing and Rafal P. Witek joins as Head of Therapeutic Cell Platforms
VANCOUVER, British Columbia – September 28, 2021 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce the addition of regenerative medicine and therapeutic development experts to our leadership team: Jack
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D bioprinting platform with JSR’s advanced materials technology to develop implantable vascula
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mediterranean to be held virtually April 6-9, 2021. This is the second time that the company will be presenting at this conference. The Business Development Team from Aspect Biosystems will also be in attendance to participate in 1-on-1 partnering meetings. To arrange
Aspect Biosystems, a biotechnology company developing bioprinted therapeutics, is pleased to announce the appointment of Ray Smith as its new Chief Financial Officer. In his role as Chief Financial Officer, Ray will assume leadership responsibilities for financial management and business operations.
“Since leaving the University of British Columbia’s campus and launching our commercial operations in 2016, Aspect has established itself as a global leader in reg
Aspect Biosystems announced today that Tamer Mohamed, Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16, 2020. This is the second time that Aspect Biosystems will be presenting at this conference.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 dedicated company presenta